MRZM.OTC.PinkMarizyme, INC

8-K: Marizyme, Inc. Initiates Asset Liquidation Process

Sentiment:

Liquidation Announcement


Marizyme, Inc. has entered into an assignment for the benefit of creditors, effectively initiating a liquidation of all company assets.

Worse than expectedThe company has declared insolvency and is liquidating all assets, which is the worst possible outcome for shareholders.

Summary

  • Marizyme, Inc. has formally entered into an Assignment for the Benefit of Creditors (ABC) agreement.
  • The Board of Directors determined that the company is unable to pay its debts as they become due.
  • All or substantially all of the company's assets have been transferred to an assignee, Peter Hurwitz.
  • The assignee is tasked with liquidating the assets to pay creditors in accordance with Florida Statutes Chapter 727.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this as a catastrophic event for investors, as the company has officially entered a liquidation process, signaling the end of its operations.

Positives

  • The company is taking proactive legal steps to address its insolvency through a structured liquidation process.

Negatives

  • The company is insolvent and unable to meet its financial obligations.
  • The business is effectively ceasing operations as all assets are being transferred for liquidation.
  • Shareholders are highly unlikely to receive any recovery given the priority of creditors in an ABC proceeding.

Risks

  • Total loss of shareholder equity.
  • Inability of the estate to generate sufficient proceeds to satisfy all outstanding debts.
  • Potential for legal or administrative complications during the liquidation process.

Future Outlook

The company is undergoing liquidation; there is no future operational outlook as the entity is transferring all assets to an assignee for the purpose of winding down affairs.

Industry Context

StockSavvy.ai notes that this filing represents a terminal event for the company, common in the medical technology sector when development-stage firms fail to secure necessary follow-on funding or achieve commercial viability.

Comparison to Industry Standards

  • The use of an Assignment for the Benefit of Creditors (ABC) is a standard, albeit final, alternative to formal Chapter 7 bankruptcy in the United States, often chosen for its potential speed and lower administrative costs compared to federal court proceedings.

Legal Proceedings

  • The company is initiating an assignment for the benefit of creditors proceeding under Chapter 727, Florida Statutes.

Stakeholder Impact

  • Shareholders face a total loss of investment value.
  • Creditors will be paid on a pro-rata basis from the proceeds of the liquidated assets.
  • Employees and suppliers are likely to face termination of contracts and outstanding payment issues.

Next Steps

  • Assignee to file a petition in the Circuit Court of the Fifteenth Judicial Circuit in Florida.
  • Assignee to take possession of and liquidate all company assets.
  • Assignee to distribute proceeds to creditors based on statutory priority.

Key Dates

DateDescription
2026-04-09Board of Directors authorized the assignment for the benefit of creditors.
2026-04-13Verification of assignment signed by CEO David Barthel.
2026-04-14Assignment Agreement entered into and executed.
2026-04-17Deadline for the assignee to file the petition in the Circuit Court of the Fifteenth Judicial Circuit in Florida.

Recommendation

strong sell

The company is in liquidation and has no remaining operational value for equity holders; the stock is effectively worthless.

Keywords

liquidation, insolvency, assignment for the benefit of creditors, bankruptcy, Marizyme, asset sale

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.